Oliver Luxxe Assets LLC Sells 7,782 Shares of ANI Pharmaceuticals, Inc. $ANIP

Oliver Luxxe Assets LLC cut its position in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 24.7% in the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 23,738 shares of the specialty pharmaceutical company’s stock after selling 7,782 shares during the quarter. Oliver Luxxe Assets LLC owned 0.10% of ANI Pharmaceuticals worth $1,965,000 as of its most recent SEC filing.

Other hedge funds also recently made changes to their positions in the company. Vanguard Group Inc. increased its position in shares of ANI Pharmaceuticals by 2.2% in the fourth quarter. Vanguard Group Inc. now owns 1,305,068 shares of the specialty pharmaceutical company’s stock valued at $103,022,000 after acquiring an additional 27,598 shares during the last quarter. State Street Corp lifted its holdings in ANI Pharmaceuticals by 2.2% during the 4th quarter. State Street Corp now owns 727,204 shares of the specialty pharmaceutical company’s stock valued at $57,405,000 after purchasing an additional 15,496 shares during the last quarter. UBS Group AG lifted its stake in shares of ANI Pharmaceuticals by 45.8% during the 3rd quarter. UBS Group AG now owns 589,874 shares of the specialty pharmaceutical company’s stock worth $54,032,000 after buying an additional 185,172 shares during the last quarter. Arrowstreet Capital Limited Partnership boosted its holdings in shares of ANI Pharmaceuticals by 19.3% during the first quarter. Arrowstreet Capital Limited Partnership now owns 564,360 shares of the specialty pharmaceutical company’s stock worth $43,399,000 after acquiring an additional 91,153 shares during the period. Finally, Dimensional Fund Advisors LP boosted its stake in ANI Pharmaceuticals by 8.9% in the 1st quarter. Dimensional Fund Advisors LP now owns 531,190 shares of the specialty pharmaceutical company’s stock valued at $40,843,000 after purchasing an additional 43,523 shares during the period. 76.05% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several research analysts have recently commented on the stock. Weiss Ratings raised shares of ANI Pharmaceuticals from a “hold (c+)” rating to a “buy (b-)” rating in a report on Tuesday, June 23rd. Zacks Research lowered ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Thursday, May 14th. Canaccord Genuity Group started coverage on ANI Pharmaceuticals in a research report on Thursday, July 16th. They set a “hold” rating and a $91.00 target price for the company. Guggenheim reissued a “buy” rating and set a $124.00 target price on shares of ANI Pharmaceuticals in a report on Friday, July 10th. Finally, Wall Street Zen cut ANI Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Saturday. Five investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat.com, ANI Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average target price of $106.83.

ANI Pharmaceuticals Stock Performance

NASDAQ ANIP opened at $78.25 on Friday. The company has a current ratio of 3.12, a quick ratio of 2.52 and a debt-to-equity ratio of 1.06. The firm has a market capitalization of $1.78 billion, a price-to-earnings ratio of 16.86 and a beta of 0.44. The firm’s 50 day simple moving average is $81.02 and its 200 day simple moving average is $79.37. ANI Pharmaceuticals, Inc. has a 1 year low of $70.15 and a 1 year high of $99.50.

ANI Pharmaceuticals (NASDAQ:ANIP) last announced its quarterly earnings data on Friday, August 7th. The specialty pharmaceutical company reported $2.21 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.04 by $0.17. ANI Pharmaceuticals had a net margin of 9.98% and a return on equity of 27.51%. The business had revenue of $266.04 million for the quarter, compared to analysts’ expectations of $260.13 million. During the same period last year, the firm posted $1.80 earnings per share. The firm’s quarterly revenue was up 25.8% compared to the same quarter last year. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. As a group, research analysts expect that ANI Pharmaceuticals, Inc. will post 8.03 earnings per share for the current fiscal year.

Insider Transactions at ANI Pharmaceuticals

In other news, Director Thomas Haughey sold 2,000 shares of ANI Pharmaceuticals stock in a transaction on Monday, June 8th. The stock was sold at an average price of $80.88, for a total value of $161,760.00. Following the transaction, the director owned 38,878 shares in the company, valued at approximately $3,144,452.64. This trade represents a 4.89% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Stephen P. Carey sold 2,850 shares of the business’s stock in a transaction on Wednesday, July 29th. The stock was sold at an average price of $81.36, for a total value of $231,876.00. Following the transaction, the chief financial officer directly owned 174,693 shares of the company’s stock, valued at $14,213,022.48. This trade represents a 1.61% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 88,029 shares of company stock worth $6,954,472. 8.10% of the stock is owned by insiders.

Key Stories Impacting ANI Pharmaceuticals

Here are the key news stories impacting ANI Pharmaceuticals this week:

• Positive Sentiment: Second-quarter adjusted earnings per share were $2.21, exceeding the roughly $2.01-$2.04 consensus range, while revenue of $266.0 million surpassed estimates near $260 million. Revenue increased 25.9% year over year, and adjusted EBITDA rose 32.4% to $71.6 million. ANI Pharmaceuticals Q2 Earnings and Revenues Beat Estimates
• Positive Sentiment: Purified Cortrophin Gel revenue climbed 43.5% to $117.1 million. Management said the expansion into podiatrists and primary-care physicians for acute gout was fully operational by June, with encouraging early prescribing and patient-case trends. ANI Pharmaceuticals Reports Record Second Quarter 2026 Financial Results
• Positive Sentiment: ANI reaffirmed full-year 2026 revenue guidance of $1.08 billion-$1.14 billion, adjusted EBITDA of $285 million-$300 million and adjusted EPS of $9.19-$9.69, above the prior consensus EPS estimate of $9.10. The company also has authorization for up to $100 million in share repurchases through May 2029. ANI Pharmaceuticals Reports Second-Quarter 2026 Results
• Neutral Sentiment: Generics revenue increased 9.7% to $99.1 million, supported by new launches, while ANI reported 12 generic launches year to date and remains on track for at least 15 in 2026.
• Negative Sentiment: ANI reduced its 2026 Cortrophin Gel revenue target to $520 million-$540 million from $540 million-$575 million. Although the revised range still implies 50%-55% growth, the cut may have disappointed investors expecting stronger near-term performance.
• Negative Sentiment: Gross margin fell to 62.4% from 64.7%, partly because of a greater mix of royalty-bearing products. Selling, general and administrative costs rose 12.1% as ANI expanded its rare-disease sales force for the gout opportunity.
• Negative Sentiment: ILUVIEN revenue declined 16.1% to $18.7 million because of international shipment timing, while Brands revenue fell 10.5% amid normalized demand.

ANI Pharmaceuticals Profile

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.